Raymond James analyst Timur Ivannikov downgraded AnaptysBio to Market Perform from Outperform without a price target. On Thursday, AnaptysBio rolled out the development plan for ~2 years and announced rosnilimab will be discontinued in alopecia areata tollowing an interim blinded review, Ivannikov tells investors in a research note. The analyst is "skeptical" of the ANB032 Phase 2b study in atopic dermatitis due to lower TH 2 activity and unproven mechanism of action.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ANAB:
- AnaptysBio announces portfolio update, discloses $575M in cash to end 2022
- AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
- AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
- AnaptysBio, GSK announces Phase 3 RUBY trial results for JEMPERLI
- AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
